Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|May 2, 2008
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancerEva Martinez-Balibrea, Albert Abad, Enrique Aranda, et al.
Scientific Reports|April 20, 2016
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathwayVicenç Ruiz de Porras, Sara Bystrup, Anna Martínez-Cardús, et al.
Acta Oncologica (Stockholm, Sweden)|October 25, 2007
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II studyAlbert Abad, Bartomeu Massuti, Antonio Antón, et al.
Journal of the National Cancer Institute|November 26, 2013
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancerCatia Moutinho, Anna Martinez-Cardús, Cristina Santos, et al.
The Oncologist|May 31, 2012
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors studyJavier Sastre, M Luisa Maestro, Auxiliadora Gómez-España, et al.
Critical Reviews in Oncology/Hematology|December 30, 2008
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III studyJavier Sastre, Enrique Aranda, Bartomeu Massutí, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Alfredo Carrato, Albert Abad, Bartomeu Massuti, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 14, 2005
A panel discussion of controversies and challenges in the adjuvant treatment of colon cancerEduardo Díaz-Rubio García, Albert Abad Esteve, Antonio Antón Torres, et al.
ESMO Open|December 6, 2019
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trialsManuel Benavides, Eduardo Díaz-Rubio, Alfredo Carrato, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 7, 2021
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Manuel Benavides, Auxiliadora Gómez-España, Pilar García-Alfonso, et al.
Pageof 4